These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35636789)

  • 1. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.
    Kasi PM; Chakrabarti S; Sawyer S; Krainock M; Poklepovic A; Ansstas G; Maninder M; Malhotra M; Ensor J; Gao L; Eroglu Z; Ellers S; Billings P; Rodriguez A; Aleshin A
    BMJ Open; 2022 May; 12(5):e060342. PubMed ID: 35636789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study).
    Hashimoto T; Tsukada Y; Ito M; Kanato K; Mizusawa J; Fukuda H; Tsukamoto S; Takashima A; Kanemitsu Y
    BMJ Open; 2023 Aug; 13(8):e073217. PubMed ID: 37586869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
    Bratman SV; Yang SYC; Iafolla MAJ; Liu Z; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Shchegrova S; Louie M; Billings P; Zimmermann B; Sethi H; Aleshin A; Torti D; Marsh K; Eagles J; Cirlan I; Hanna Y; Clouthier DL; Lien SC; Ohashi PS; Xu W; Siu LL; Pugh TJ
    Nat Cancer; 2020 Sep; 1(9):873-881. PubMed ID: 35121950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.
    Hernando-Calvo A; Yang SYC; Vila-Casadesús M; Han M; Liu ZA; Berman AHK; Spreafico A; Razak AA; Lheureux S; Hansen AR; Lo Giacco D; Abbas-Aghababazadeh F; Matito J; Haibe-Kains B; Pugh TJ; Bratman SV; Aleshin A; Berche R; Saavedra O; Garralda E; Elston S; Siu LL; Ohashi PS; Vivancos A; Bedard PL
    JCO Precis Oncol; 2024 Aug; 8():e2400100. PubMed ID: 39178369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes.
    Kasi PM; Bucheit LA; Liao J; Starr J; Barata P; Klempner SJ; Gandara D; Shergill A; Madeira da Silva L; Weipert C; Zhang N; Pretz C; Hardin A; Kiedrowski LA; Odegaard JI
    JCO Precis Oncol; 2023 Sep; 7():e2300118. PubMed ID: 37769226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
    Allin DM; Shaikh R; Carter P; Thway K; Sharabiani MTA; Gonzales-de-Castro D; O'Leary B; Garcia-Murillas I; Bhide S; Hubank M; Harrington K; Kim D; Newbold K
    Eur J Cancer; 2018 Nov; 103():165-175. PubMed ID: 30253333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis.
    Bui NQ; Nemat-Gorgani N; Subramanian A; Torres IA; Lohman M; Sears TJ; van de Rijn M; Charville GW; Becker HC; Wang DS; Hwang GL; Ganjoo KN; Moding EJ
    Clin Cancer Res; 2023 Jul; 29(14):2612-2620. PubMed ID: 37130154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.
    Sanz-Garcia E; Genta S; Chen X; Ou Q; Araujo DV; Abdul Razak AR; Hansen AR; Spreafico A; Bao H; Wu X; Siu LL; Bedard PL
    JCO Precis Oncol; 2023 Apr; 7():e2200509. PubMed ID: 37027812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
    Jang A; Lanka SM; Jaeger EB; Lieberman A; Huang M; Sartor AO; Mendiratta P; Brown JR; Garcia JA; Farmer T; Sudhaman S; Mahmood T; Pajak N; Calhoun M; Dutta P; ElNaggar A; Liu MC; Barata PC
    JCO Precis Oncol; 2023 Jul; 7():e2300131. PubMed ID: 37467457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
    Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
    Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
    Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
    Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
    [No Abstract]   [Full Text] [Related]  

  • 16. Practical recommendations for using ctDNA in clinical decision making.
    Cohen SA; Liu MC; Aleshin A
    Nature; 2023 Jul; 619(7969):259-268. PubMed ID: 37438589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.
    Chen K; Zhao H; Yang F; Hui B; Wang T; Wang LT; Shi Y; Wang J
    BMJ Open; 2018 Feb; 8(2):e019012. PubMed ID: 29437753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Lakhotia R; Roschewski M
    Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Circulating Tumor DNA for Cancer Immunotherapy.
    Snyder A; Morrissey MP; Hellmann MD
    Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.